ClearPoint Neuro/$CLPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ClearPoint Neuro
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Ticker
$CLPT
Sector
Primary listing
Employees
115
Headquarters
Website
ClearPoint Neuro Metrics
BasicAdvanced
$315M
-
-$0.80
0.85
-
Price and volume
Market cap
$315M
Beta
0.85
52-week high
$19.22
52-week low
$9.76
Average daily volume
358K
Financial strength
Current ratio
7.298
Quick ratio
6.271
Long term debt to equity
177.911
Total debt to equity
179.588
Profitability
EBITDA (TTM)
-21.645
Gross margin (TTM)
60.42%
Net profit margin (TTM)
-66.15%
Operating margin (TTM)
-67.42%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-24.52%
Return on equity (TTM)
-85.68%
Valuation
Price to revenue (TTM)
9.167
Price to book
15.95
Price to tangible book (TTM)
15.95
Price to free cash flow (TTM)
-26.286
Free cash flow yield (TTM)
-3.80%
Free cash flow per share (TTM)
-0.422
Growth
Revenue change (TTM)
19.68%
Earnings per share change (TTM)
13.58%
3-year revenue growth (CAGR)
20.74%
10-year revenue growth (CAGR)
25.63%
3-year earnings per share growth (CAGR)
3.24%
10-year earnings per share growth (CAGR)
-21.12%
What the Analysts think about ClearPoint Neuro
Analyst ratings (Buy, Hold, Sell) for ClearPoint Neuro stock.
Bulls say / Bears say
ClearPoint posted record revenue of $9.2 million for Q2 2025, up 17% year-over-year, led by a 33% jump in neurosurgery navigation and therapy revenue thanks to SmartFrame and PRISM Laser Therapy products. (Stock Titan)
The company secured up to $105 million in financing from Oberland Capital, including $30 million funded at closing and an added $3.5 million equity infusion, raising cash on hand to $41.5 million as of June 30, 2025—up from $20.1 million at the end of 2024. (Stock Titan)
Three Wall Street analysts maintain a consensus Buy rating on CLPT, with an average 12-month price target of $25.00 that implies a 122.6% gain from current levels. (MarketBeat)
Net loss increased to $5.8 million ($0.21 per share) in Q2 2025 from $4.4 million the previous year, indicating higher cash burn and continued pressure on profitability. (Stock Titan)
Operating expenses rose 16% year-over-year to $11.2 million in Q2 2025, growing faster than revenue and reflecting increased spending on R&D and commercialization. (Stock Titan)
In Q4 2024, CLPT posted an adjusted loss per share of $0.20, falling short of the Zacks consensus estimate for a $0.15 loss and resulting in a 33.3% negative earnings surprise. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 13 Aug 2025.
ClearPoint Neuro Financial Performance
Revenues and expenses
ClearPoint Neuro Earnings Performance
Company profitability
ClearPoint Neuro News
AllArticlesVideos
ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners
Accesswire19 hours ago
ClearPoint Neuro Reports Second Quarter 2025 Results
Accesswire3 weeks ago
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
Accesswire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ClearPoint Neuro stock?
ClearPoint Neuro (CLPT) has a market cap of $315M as of September 05, 2025.
What is the P/E ratio for ClearPoint Neuro stock?
The price to earnings (P/E) ratio for ClearPoint Neuro (CLPT) stock is 0 as of September 05, 2025.
Does ClearPoint Neuro stock pay dividends?
No, ClearPoint Neuro (CLPT) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next ClearPoint Neuro dividend payment date?
ClearPoint Neuro (CLPT) stock does not pay dividends to its shareholders.
What is the beta indicator for ClearPoint Neuro?
ClearPoint Neuro (CLPT) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.